Cornelia L. Dekker, M.D.

Clinical Focus

• Pediatric Infectious Disease
• Vaccine Clinical Trials
• Vaccine Safety
• Infectious Diseases, Pediatric

Administrative Appointments

• Medical Director, Stanford-LPCH Vaccine Program , (1999– present )
• Member, National Vaccine Advisory Committee (NVAC) , (2005– 2010 )
• Member, NVAC H1N1 Subgroup , (2009– present )
• Member, NVAC Vaccine Safety Working Group , (2008– 2010 )
• Co-chair, NVAC Subcommittee on Vaccine Development and Supply , (2005– 2008 )
• Co-chair, NVAC Working Group on Regulatory Harmonization , (2005– 2006 )
• Member, HIV Vaccine Trial Network Safety Monitoring Board , (2009– present )
• IRB Reviewer, Stanford Administrative Panel on Human Subjects in Medical Research, Panel 3 , (2002– present )
• Member, Stanford GCRC Advisory Committee , (2006– present )
• Member and SMC Chair (Pediatric), NIH DMID/Sanofi Pasteur Inactivated Influenza A/H5N1 Vaccine Data Safety Monitoring Board , (2005– 2007 )
• Member, NIH DMID Phase 1A Clinical Study with DAS181 Safety Monitoring Committee , (2007– present )
• Member, NIH DMID Evaluation of a Challenge Pool of Norwalk Virus Inocula in Human Subjects SMC , (2008– present )
• Member, Trustee Committee, California Association of Independent Schools , (2004– 2007 )
• President, Bentley School Board of Trustees , (2001– 2004 )

Honors and Awards

• Junior Faculty Award, SmithKlein Beecham (07/05/00-07/04/02)
• Excellence in Teaching, Stanford Univ. School of Medicine (06/23/08)

Professional Education

• Board Certification: General Pediatrics, American Board of Pediatrics (1981)
• Duke University Medical Center (1982) NC
• Duke University Medical Center (1979) NC
• Duke University Medical Center (1977) NC
• Michigan State University (1976) MI
• B.S., Michigan State University Microbiology & Public Health, Human Clinical Medicine (1973)
• M.D., Michigan State University Medicine (1976)

Postdoctoral Advisees

• Barbara Pahud

Graduate & Fellowship Program Affiliations

• Medicine
• Infectious Diseases
• Pediatrics

Web Site Links

• Vaccine Program Web site

Research Interests

The overarching theme of our research activities is human response to natural virus infection and to vaccines. We have conducted several studies of adult, toddler and infant immune response to initial infection with human cytomegalovirus (HCMV). Our latest is a large-scale project in which we have screened 20,000 newborn infants at Stanford, El Camino and Santa Clara Valley Hospitals for evidence of congenital HCMV infection. Those infants identified as being infected are enrolled into a 3-year prospective study for medical, audiology and immunology screening. The hearing screening portion is designed to identify, as early as possible, infants who develop sensorineural hearing loss as a result of this infection.

A second area of clinical research is supported by Dr. Ann Arvin and Dr. Mark Davis' NIH-funded U19 project entitled "Protective Mechanisms Against Pandemic Respiratory Virus". To support the lab projects we immunize children and adults (including elderly)with one of two different, licensed influenza vaccines to study in detail the immune response to immunization. The two vaccine preparations are live, attenuated influenza vaccine given intranasally, and inactivated vaccine given intramuscularly. Blood samples collected from study subjects are analyzed for traditional antibody, B-cell Elispot, CD4 and CD8 T-cell responses and NK-cell responses by Stanford collaborators.

Our group also is funded as part of the Vaccine Treatment and Evaluation Units by NIH through our collaborators at Vanderbilt University. We are conducting studies of avian and seasonal influenza vaccines and a new malaria vaccine.

A fourth area of interest is vaccine safety. Stanford is one of six designated Centers for Immunization Safety Assessment (CISA) sponsored by the CDC. The network provides consultation to CDC on evaluation and treatment of adverse events following immunization with licensed vaccines, develops protocols to study certain events that occur following immunization (including hypersensitivity reactions, safety of live viral vaccines in immunodeficient children, Guillain-Barre syndrome).

In addition to the above-mentioned, government-supported research activities, we also conduct clinical studies of vaccines sponsored by the vaccine industry. For further information about ongoing studies, please refer to our website at http://vaccines.stanford.edu.

Publications

• Adolescent vaccination: recommendations from the National Vaccine Advisory Committee. Stokley S, Freed G, Curtis R, Gordon L, Humiston S, Parnell T, Pavia A, Young A, Johnson D, Kennedy A, Hopfensperger D, Markowitz L, Fergie J, Koslap-Petraco MB, McCauley M.  Am J Prev Med.  2009; 36 (3): 278-9.e6
• Differential maternal responses to a newly developed vaccine information pamphlet. Klein NP,  Kissner J, Aguirre A, Sparks R, Campbell S, Edwards KM, Dekker CL, Shui I, Gust DA.  Vaccine.  2009;
• Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Keitel WA,  Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H.  Vaccine.  2009; 27 (47): 6642-8
• One step closer to a CMV vaccine. Dekker CL,  Arvin AM.  N Engl J Med.  2009; 360 (12): 1250-2
• An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Wood RA,  Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, Halsey NA.  Pediatrics.  2008; 122 (3): e771-7
• Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Talbot HK,  Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM.  Vaccine.  2008; 26 (32): 4057-61
• Influence of prior influenza vaccination on antibody and B-cell responses. Sasaki S,  He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB.  PLoS One.  2008; 3 (8): e2975
• Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. He XS,  Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, Arvin AM, Greenberg HB.  PLoS One.  2008; 3 (7): e2574
• Mandates for adolescent immunizations: recommendations from the National Vaccine Advisory Committee. Am J Prev Med.  2008; 35 (2): 145-51
• Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. He XS,  Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB.  J Infect Dis.  2008; 197 (6): 803-11
• Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Bernstein DI,  Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H.  J Infect Dis.  2008; 197 (5): 667-75
• The promise and challenge of adolescent immunization. Am J Prev Med.  2008; 35 (2): 152-7
• Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. Sasaki S,  Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB.  J Virol.  2007; 81 (1): 215-28
• Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Zeman AM,  Holmes TH, Stamatis S, Tu W, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL.  Pediatr Infect Dis J.  2007; 26 (2): 107-15
• A role for genetics in the immune response to the varicella vaccine. Klein NP,  Fireman B, Enright A, Ray P, Black S, Dekker CL.  Pediatr Infect Dis J.  2007; 26 (4): 300-5
• Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. He XS,  Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM.  J Virol.  2006; 80 (23): 11756-66
• Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Klein NP,  Holmes TH, Sharp MA, Heineman TC, Schleiss MR, Bernstein DI, Kemble G, Arvin AM, Dekker CL.  Vaccine.  2006; 24 (33-34): 5913-8
• Selective developmental defects of cord blood antigen-presenting cell subsets. Drohan L,  Harding JJ, Holm B, Cordoba-Tongson E, Dekker CL, Holmes T, Maecker H, Mellins ED.  Hum Immunol.  2004; 65 (11): 1356-69
• T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. He XS,  Draghi M, Mahmood K, Holmes TH, Kemble GW, Dekker CL, Arvin AM, Parham P, Greenberg HB.  J Clin Invest.  2004; 114 (12): 1812-9
• Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. Tu W,  Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC, Maecker HT, Holmes TH, Wang Z, Kemble G, Adler S, Arvin A, Lewis DB.  J Immunol.  2004; 172 (5): 3260-7
• Intestinal imaging of children with acute rotavirus gastroenteritis. Bass D,  Cordoba E, Dekker C, Schuind A, Cassady C.  J Pediatr Gastroenterol Nutr.  2004; 39 (3): 270-4
• Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. Chen SF,  Tu WW, Sharp MA, Tongson EC, He XS, Greenberg HB, Holmes TH, Wang Z, Kemble G, Manganello AM, Adler SP, Dekker CL, Lewis DB, Arvin AM.  J Infect Dis.  2004; 189 (9): 1619-27
• Pediatric uses of valacyclovir, penciclovir and famciclovir. Dekker CL,  Prober CG.  Pediatr Infect Dis J.  2001; 20 (11): 1079-81
• Antiviral agents effective against herpesviruses. Dekker CL,  Prober CG.  Curr Clin Top Infect Dis.  2001; 21 271-301
• Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Corey L,  Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE.  JAMA.  1999; 282 (4): 331-40
• Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Black SB,  Shinefield HR, Bergen R, Hart C, Kremers R, Lavetter A, Lemesurier J, Morozumi PA, Ray P, Lewis EM, Fireman B, Schwalbe J, Hallam P, Shandling M, Dekker C, Granoff DM, Izu A, Podda A.  Pediatr Infect Dis J.  1997; 16 (1): 53-8
• Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. Straus SE,  Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, Lekstrom J, Cox E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L.  J Infect Dis.  1997; 176 (5): 1129-34
• Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC,  Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.  AIDS Res Hum Retroviruses.  1996; 12 (8): 683-93
• A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected] Langenberg AG,  Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L.  Ann Intern Med.  1995; 122 (12): 889-98
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Kahn JO,  Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D.  J Infect Dis.  1994; 170 (5): 1288-91
• Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Keitel W,  Couch R, Bond N, Adair S, Van Nest G, Dekker C.  Vaccine.  1993; 11 (9): 909-13
• Unrecognized pertussis infection in adolescents. Cromer BA,  Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA.  Am J Dis Child.  1993; 147 (5): 575-7
• Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Morgan CM,  Blumberg DA, Cherry JD, Reisinger KS, Blatter MM, Blumer JL, Dekker CL, Stout MG, Christenson PD.  Am J Dis Child.  1990; 144 (1): 41-5
• Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Mortimer EA,  Kimura M, Cherry JD, Kuno-Sakai H, Stout MG, Dekker CL, Hayashi R, Miyamoto Y, Scott JV, Aoyama T.  Am J Dis Child.  1990; 144 (8): 899-904
• Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. Blumberg DA,  Mink CM, Cherry JD, Reisinger KS, Blatter MM, Congeni BL, Dekker CL, Stout MG, Mezzatesta JR, Scott JV.  J Pediatr.  1990; 117 (1 Pt 1): 46-51
• In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. McLaren C,  Corey L, Dekket C, Barry DW.  J Infect Dis.  1983; 148 (5): 868-75
• Virus resistance in clinical practice. Dekker C,  Ellis MN, McLaren C, Hunter G, Rogers J, Barry DW.  J Antimicrob Chemother.  1983; 12 Suppl B 137-52
• Ocular lesions in mice following intracerebral injection of herpes simplex virus type I. Peiffer RL,  Dekker CD, Siegel FL.  Invest Ophthalmol Vis Sci.  1983; 24 (8): 1070-8